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Abstract: Several biological agents have been added to our armamentarium of treatment options for moderate to severely active inﬂammatory bowel
diseases, and this number is expected to only increase in the near future. With our growing understanding of disease mechanisms and pharmacokinetics,
we are now able to target several mechanisms of action to achieve key endpoints (steroid-free remission and mucosal healing) associated with improved
long-term disease-related outcomes. In this context, concerns arise regarding the optimal positioning of currently available biologics and key biologics in
development. In this review, we will discuss the currently available evidence for comparative effectiveness of biological agents approved for the use in
moderate to severely active inﬂammatory bowel diseases, with a focus on practical considerations to be made when using these agents in practice. We
will further review novel biological agents and small molecule inhibitors in development and discuss future opportunities through which providers may
personalize treatment decisions to achieve optimal treatment outcomes.
(Inﬂamm Bowel Dis 2016;22:998–1009)
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U lcerative colitis (UC) and Crohn’s disease (CD) are chronicinﬂammatory bowel diseases (IBD) characterized by recur-
rent episodes of intestinal inﬂammation and mucosal ulceration.1–3
Historically, patients with IBD were treated sequentially using ste-
roids and nonspeciﬁc immunosuppressive agents (azathioprine, 6-
mercaptopurine, and methotrexate) with the intent of reducing
disease-related symptoms (diarrhea, abdominal pain, and fatigue).
Accordingly, disease monitoring was largely based on the subjec-
tive assessment of symptom severity, and individual expectations
for treatment outcomes were uncertain and unpredictable.4–8 When
inﬂiximab was approved for IBD, expectations for what outcomes
are possible with treatment changed and subsequently the concept
of personalized medicine evolved.
Initially, evidence established that using tumor necrosis
factor (TNF) antagonists in combination with azathioprine early
in the disease course (top down) was more effective than the
classic sequential step-up approach in moderate to severely active
CD.9 Then, it was demonstrated that the addition of an immuno-
suppressive agent to TNF antagonist therapy improves treatment
efﬁcacy beyond that seen with TNF antagonist or immunosup-
pressive monotherapy in naive patients to both therapies, and this
improved efﬁcacy is at least in part driven by the prevention of
immunogenicity and optimization of biological drug concentra-
tions.10–12 More recently, it has been established that early com-
bined immunosuppression with frequent monitoring of disease
activity and drug concentrations has a substantial impact on
treatment-related costs and disease-related complications (hospi-
talizations, surgeries, and overall complications).13,14 Efforts have
therefore now focused on optimizing individual treatment deci-
sions and biological dosing through frequent monitoring with the
intent of achieving clinical endpoints that accurately predict
disease-related complications (i.e., mucosal healing).6,15
Although considerable strides have been made in the
optimization of treatment outcomes for IBD, patients with IBD
continue to have a greater per-patient expenditure than many other
chronic health conditions in the United States, and most of this
cost is driven using biological agents.16–18 With the growing
understanding of the disease mechanisms central to the pathogen-
esis of IBD, a surge of innovation has occurred with the devel-
opment of several new classes of biological agents, which are in
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various phases of development or introduction into clinical prac-
tice. This, coupled with the increasing potential to offset the nat-
ural progression and disease complications through personalized
therapeutic decisions, will result in a substantial increase in the
use of biological agents among patients with IBD over time. The
exact positioning and integration of currently available biologics
and key biologics in development, the impact they will have on
disease outcomes, and the optimal approach to monitoring and
adjusting these therapies, however, remains to be determined. In
this review article, we will discuss the comparative effectiveness
of currently approved biologics and key biologics in development
for IBD. We will further discuss the importance of drug concen-
tration monitoring, treatment adherence, and how providers may
optimize these 2 factors. Finally, we will highlight future oppor-
tunities to engage in personalized medicine and the evolving role
of biosimilars.
TNF ANTAGONISTS AND VEDOLIZUMAB:
COMPARATIVE EFFECTIVENESS OF CURRENTLY
APPROVED BIOLOGICS
When comparing efﬁcacy across agents and trials, we have
2 ways to accomplish this, direct and indirect comparisons. Direct
comparisons of biologics through large well-powered randomized
head-to-head trials are yet to be conducted within IBD, and
therefore, we must rely on indirect treatment comparisons.
Network meta-analyses (NMAs) can help assess comparative
effectiveness of multiple interventions and synthesize evidence
across a network of randomized controlled trials (RCTs), by
simultaneous analysis of direct evidence (from head-to-head trials
of active agents) and indirect evidence (from RCTs comparing
treatments of interest with a common comparator, usually
placebo), to calculate a mixed effect estimate as the weighted
average of the 2. Such a technique can improve the precision of
the estimate (compared with direct evidence alone) and also
allows estimation of the comparative efﬁcacy of 2 active treat-
ments, even if no studies directly compare them. However, NMAs
do rely on the assumption that no signiﬁcant differences exist
between trials or between common comparator populations
(similarity assumption).19,20 Such an assumption may not be ade-
quately satisﬁed in trials of biological agents for IBD, because of
considerable differences in study design, patient population, co-
interventions, and outcome assessment for trials of different bio-
logics. Therefore, caution must be exercised when interpreting
results of NMAs of biological agents in IBD.
Crohn’s Disease
Induction of Clinical Remission
When considering pivotal RCTs of currently approved
biologics for luminal moderate to severe CD, within-study
treatment effect size (delta between intervention and placebo)
for induction of clinical remission (Crohn’s Disease Activity
Index [CDAI] ,150) is larger with TNF antagonists as compared
with vedolizumab, with inﬂiximab and adalimumab appearing to
have the greatest measurable treatment effect size21–25 (Fig. 1). A
series of recent indirect treatment comparisons have used the
statistical technique of Bayesian NMAs to infer on these compar-
isons across these trials and have generally suggested that inﬂix-
imab and adalimumab may be superior to certolizumab pegol and
vedolizumab for induction of remission.26–28 Stidham et al26 per-
formed an NMA of all TNF antagonists in CD, which included all
FIGURE 1. Incremental beneﬁt (delta) of currently approved biologics for induction and maintenance of remission in Crohn’s disease. CSFREM,
corticosteroid-free remission.
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patients irrespective of previous biological exposure status, and
found that adalimumab may be superior to certolizumab pegol
(relative risk [RR] 2.93, 95% credible interval [CrI] 1.21–7.75)
for induction of clinical remission, but comparisons between in-
ﬂiximab and adalimumab (RR 1.52, 95% CrI 0.20–17.46) or in-
ﬂiximab and certolizumab pegol (RR 4.29, 95% CrI 0.65–46.09)
did not reach statistical signiﬁcance. Hazlewood et al28 expanded
this search to include vedolizumab and immunosuppressive
agents (azathioprine, 6-mercaptopurine, and methotrexate),
including trials of concomitant immunosuppressive therapy with
TNF antagonists, and similarly found that adalimumab may be
superior to certolizumab pegol (odds ratio [OR] 2.1, 95% CrI 1.0–
4.6), and the combination of inﬂiximab with azathioprine (OR
3.1, 95% CrI 1.4–7.7) but not inﬂiximab alone (OR 2.1, 95%
CrI 0.98–5.5) may be superior to certolizumab pegol. When lim-
iting this analysis to a subset of biological-naive patients with CD,
Singh et al27 found that inﬂiximab was superior to all other bio-
logics (certolizumab pegol: RR 0.24, 95% CrI 0.07–0.73; natali-
zumab: RR 0.22, 95% CrI 0.06–0.70; vedolizumab: RR 0.23,
95% CrI 0.06–0.78; and ustekinumab: RR 0.10, 95% CrI 0.02–
0.52) for induction of remission, with the exception of adalimu-
mab (RR 0.49, 95% CrI 0.11–1.85), but adalimumab was not
signiﬁcantly different when compared with other biologics. Sev-
eral factors need to be taken into consideration, however, when
interpreting and applying these data to routine practice.
The earlier studies for inﬂiximab and adalimumab recruited
patients with CD who were more often naive to biological therapy
as compared with the nearly 50% of patients with previous
biological exposure in the trials for certolizumab pegol and
vedolizumab, some of which had failed multiple biologics before
recruitment.23,24 This is of particular importance given the treat-
ment effect size for TNF antagonists is higher among naive pa-
tients with CD to biological therapy,25 and the subanalyses for
vedolizumab demonstrated a time-dependent treatment effect for
induction of remission in patients who had failed a previous TNF
antagonist.29 Within the GEMINI trial, the treatment effect size of
vedolizumab for induction of clinical remission in CD rose from
7% to 16% between week 6 and week 10 of therapy, and this
incremental beneﬁt from week 6 to week 10 of therapy was sub-
stantially more pronounced in patients who had failed TNF antag-
onist therapy (3% and 14.5% at week 6 and 10, respectively) as
compared with those naive to these agents (19% and 19% at week
6 and 10, respectively).29 Thus, using an earlier measure of treat-
ment effect size, the meta-analysis by Hazlewood et al28 may have
underestimated the true comparative effectiveness of vedolizu-
mab. Although the study by Singh et al27 attempted to account
for this by limiting the analysis to biological-naive patients and
using a 2 to 4 weeks of window after completion of induction
therapy for assessing outcome, only inﬂiximab reached statisti-
cally signiﬁcant superiority as compared with certolizumab pegol
and vedolizumab within this study. This is in direct contrast to the
studies by Stidham et al26 and Hazlewood et al,28 where adalimu-
mab, but not inﬂiximab, reached statistically signiﬁcant superior-
ity to these agents.
Thus, despite using similar studies for comparison, these
NMAs yielded different results which are likely due to variations in
common comparator groups. A clear example of this is seen within
the study of Hazlewood et al,28 where inﬂiximab is demonstrated to
be superior to azathioprine/6-mercaptopurine for induction of remis-
sion (OR 2.3, 95% CrI 1.3–5.0), but the combination of inﬂiximab
with methotrexate is not (OR 2.1, 95% CrI 0.67–7.9), suggesting
that methotrexate may somehow negate the efﬁcacy of inﬂiximab.
This brings up an important consideration in that most of RCTs for
biologics had a substantial minority of patients (;30%) on concom-
itant immunosuppressive therapy, and therefore, any indirect com-
parisons of biological monotherapy or biological combination
therapy (concomitant use of an immunosuppressive agent) at the
trial level should be interpreted with caution.
Maintenance of Clinical Remission
For maintenance of clinical remission in luminal moderate to
severe CD, within-study treatment effect size for maintenance of
remission and corticosteroid-free remission was again higher for
TNF antagonists, with inﬂiximab and adalimumab achieving the
highest within-study treatment effect. The differences between
biological agents, however, are much less pronounced as compared
with induction of remission data24,30–32 (Fig. 1). The NMA by
Hazlewood et al28 and Singh et al27 again demonstrated that inﬂix-
imab and adalimumab had the greatest treatment effect size and
probability of maintaining remission, but the comparative effective-
ness data of these 2 meta-analyses were discordant. Singh et al27
found no single biological to superior to another, but the study by
Hazlewood et al28 suggested that adalimumab and the combination
of inﬂiximab with azathioprine were superior to vedolizumab (OR
0.42, 95% CrI 0.22–0.85 for vedolizumab versus adalimumab and
OR 0.42, 95% CrI 0.17–0.92 for vedolizumab versus inﬂiximab +
azathioprine) and certolizumab pegol (OR 2.5, 95% CrI 1.4–4.6 for
adalimumab versus certolizumab pegol and OR 2.6, 95% CrI 1.3–
6.0 for inﬂiximab + azathioprine versus certolizumab) for mainte-
nance of clinical remission. The authors concluded that adalimu-
mab monotherapy was superior to certolizumab pegol
monotherapy, and inﬂiximab in combination with azathioprine
was superior to inﬂiximab or certolizumab pegol monotherapy
but not signiﬁcantly different when compared with adalimumab.
Providers need to remember that there were differences in
designing the maintenance phase of RCTs for biological agents
(whether randomizing at start of study or re-randomizing only
responders to induction therapy). Additionally, within the adali-
mumab studies, nearly 50% of patients were on concomitant
immunosuppressive therapy making comparisons of mono versus
combo therapy inaccurate when using these data at the trial level.
A recent systematic review aimed at speciﬁcally addressing the
role of concomitant immunosuppressive therapy with TNF
antagonists concluded that, although head-to-head RCTs are
lacking for all TNF antagonists, the use of concomitant immuno-
suppressive therapy is likely beneﬁcial for all TNF antagonists
given the clear impact it has on immunogenicity and drug
concentrations, a factor known to impact treatment outcomes.12
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Mucosal Healing, Hospitalization, and Surgery
Mucosal healing has emerged as an important clinical
outcome within IBD, and achieving mucosal healing in CD has
been associated with a reduced need for corticosteroids, hospital-
ization, and surgery.15 Within the ACCENT I trial, mucosal heal-
ing rates were noted to be as high as 44% at 1 year with scheduled
maintenance inﬂiximab therapy as compared with 18% with epi-
sodic therapy.32 Similar rates were achieved in SONIC, where
6-month mucosal healing rates were considerably higher with
inﬂiximab in combination with azathioprine (44%), as compared
with inﬂiximab (30%) or azathioprine (16%) monotherapy.10 For
adalimumab, the mucosal healing rates at 1 year within the
EXTEND trial were noted to be 24%, and for certolizumab pegol,
the mucosal healings rates at 1 year were 14%.33,34 Mucosal heal-
ing was not assessed in the GEMINI trial for CD, and the 1-year
rates for mucosal healing with vedolizumab are yet to be deter-
mined. It is important to recognize that deﬁnitions for mucosal
healing varied across studies, and early studies for biologics in
IBD did not implore centralized reading, a factor known to impact
the quality of scoring and assessment for mucosal healing.15
When considering hospitalization and surgery, in the
ACCENT I trial, patients with moderate to severe CD treated
with scheduled maintenance inﬂiximab were signiﬁcantly less
likely to require hospitalization or surgery as compared with those
treated with episodic therapy.32,35 Similarly, in the ACCENT II
trial, patients with ﬁstulizing CD who had initially responded to
inﬂiximab and then continued inﬂiximab maintenance therapy
required fewer hospitalizations, fewer days in the hospital, sur-
geries, or procedures as compared with those who received pla-
cebo.36 In 2 separate meta-analyses of RCTs and observational
studies, inﬂiximab was associated with a .50% reduction in the
need for hospitalizations (RCTs: OR 0.48, 95% conﬁdence inter-
val [CI], 0.34–0.67; observational studies: OR 0.28, 95% CI,
0.18–0.46) and nearly 70% reduction in need for surgery at 1 year
(RCTs: OR 0.31, 95% CI, 0.15–0.64; observational studies: OR
0.32, 95% CI, 0.21–0.49).36–39 Adalimumab has similarly demon-
strated a reduction in hospitalization and surgery rates, and within
the CHARM trial, the use of maintenance adalimumab in patients
initially responding to induction therapy resulted in a reduction in
hospitalization at 1 year when compared with placebo (12.6%
versus 25.2%). Within the REACT trial, the use of early com-
bined immunosuppression with adalimumab was associated with
a signiﬁcant reduction in hospitalization, complications, and sur-
gery (hazard ratio ¼ 0.74, 95% CI, 0.62–0.87).13 Long-term data
on the risk reduction for hospitalization and surgery with certoli-
zumab pegol and vedolizumab are lacking.
Ulcerative Colitis
Induction and Maintenance of Clinical Remission
and Mucosal Healing
Within-study treatment effect sizes (delta between inter-
vention and placebo) for induction of clinical remission (Mayo
Clinic score #2 and no subscore .1) and mucosal healing (Mayo
endoscopic subscore of 0 or 1) in pivotal RCTs of currently
approved biologics for moderate to severe UC are larger with
inﬂiximab as compared with vedolizumab, with golimumab and
adalimumab having substantially lower remission and mucosal
healing rates (Fig. 2). For durable remission, corticosteroid-free
remission, and mucosal healing with maintenance therapy, the
FIGURE 2. Incremental beneﬁt (delta) of currently approved biologics for induction and maintenance of remission in UC. CSFREM, corticosteroid-
free remission.
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within-study treatment effect sizes for vedolizumab and inﬂixi-
mab are very similar and substantially larger than those seen with
adalimumab and golimumab.40–44
When pooling data for comparisons across studies and
biologics, a meta-analysis by Stidham et al45 showed trends
toward favoring inﬂiximab over adalimumab (RR 2.08, 95%
CrI 0.32–12.03) and golimumab (RR 1.18, 95% CrI 0.13–
10.63) for induction and maintenance of remission, but these
comparisons did not reach statistical signiﬁcance. Similar to the
RCTs for CD, these RCTs varied considerably in patient popula-
tions with key difference in previous treatment, particularly TNF
antagonist failure. Two recent studies attempted to overcome this
by limiting the analyses to biological-naive patients. In the ﬁrst
study by Thorlund et al,46 adalimumab was less likely to achieve
clinical remission (OR 0.42, 95% CrI 0.17–0.97) or mucosal heal-
ing (OR 0.46, 95% CrI 0.25–0.86) at 8 weeks, but there was no
signiﬁcant difference between adalimumab and inﬂiximab for
week 52 outcomes. The second study by Danese et al47 observed
that inﬂiximab may be superior to adalimumab for achieving
clinical response (OR 2.36, 95% CrI 1.22–4.63), clinical remis-
sion (OR 2.78, 95% CrI 0.95–8.83), and mucosal healing (OR
2.02, 95% CrI 1.13–3.59) after induction therapy, but inﬂiximab
was similar to golimumab and vedolizumab for achieving clinical
remission (golimumab: OR 1.84, 95% CrI 0.58–6.92; vedolizu-
mab: OR 1.18, 95% CrI 0.21–6.32), and similar to golimumab for
achieving mucosal healing (OR 1.80, 95% CrI 0.96–3.46).47
Owing to differences in trial designs across agents for mainte-
nance therapy (whether randomizing at start of study or re-
randomizing only responders to induction therapy), no inference
on comparative efﬁcacy of different biologics for maintenance of
remission could be made.
Hospitalization and Surgery
Within the ACT trial, the use of inﬂiximab resulted in
a signiﬁcant reduction in the risk of colectomy at 1 year when
compared with placebo (10% versus 17%), and the rates of hospital
admissions with inﬂiximab were nearly half that seen with placebo
(20 versus 40 hospitalizations per 100 patient years).48 A post hoc
analysis of ULTRA 2 similarly demonstrated that the use of ada-
limumab induction and maintenance therapy resulted in a signiﬁcant
reduction in hospitalizations both at 8 and 52 weeks of therapy
when compared with placebo.49 A recent meta-analysis of RCTs,
however, demonstrated that although inﬂiximab and adalimumab
were both associated with a reduction in hospitalizations, only in-
ﬂiximab was associated with a reduction in colectomy rates.49,50
Data regarding the long-term impact of vedolizumab on hospitali-
zation and colectomy in UC were lacking.
IMPORTANCE OF DRUG CONCENTRATIONS AND
ITS IMPACT ON POSITIONING OF CURRENTLY
APPROVED BIOLOGICS
When considering how best to position currently available
biologics, we must take into consideration whether opportunities
exist to optimize treatment efﬁcacy on an individual basis. This is
of particular importance given most patients seen in clinical
practice would not have qualiﬁed for pivotal RCTs used to
generate treatment efﬁcacy data, and therefore, the translatability
of comparative effectiveness data to routine practice is limted.51
Monitoring serum drug concentrations is a measure of drug expo-
sure and can be associated with drug efﬁcacy. It is also a measure
of bioavailability as the absorption of biologics into the blood-
stream is variable, particularly for subcutaneously administered
drugs.52 Monoclonal antibodies typically have a steady-state vol-
ume of distribution equal to the plasma volume and are mainly
distributed within the central compartment.53 Although the phar-
macokinetics of TNF antagonists and anti-integrin biologics is
similar, their mechanism of action, and thus concentration–effect
relationship, may be different. Thus, when attempting to under-
stand the optimal positioning of individual biologics, we must
consider whether a clear association exists between drug concen-
trations and treatment outcomes, whether the optimal cut-point for
achieving maximal efﬁcacy has been identiﬁed, and whether strat-
egies are currently available to monitor and optimize dosing.
Therapies with drug monitoring capability, where drug concen-
trations are clearly linked to improved outcomes, and well de-
signed and studied strategies exist to optimize drug
concentrations, will be the favorable ﬁrst-line agents.
Clinical Impact of Drug Concentrations
For different TNF antagonists, an apparent association
between serum drug concentration and various outcome measures
has been shown, indicating that this is a class effect. In the
IMAgINE-1 study, a serum concentration-efﬁcacy relationship
was observed in pediatric patients with moderate to severe CD
treated with adalimumab.54 Similar effects were observed for pa-
tients with CD with inﬂiximab as Cornillie et al55 demonstrated
that an adequate inﬂiximab trough concentration of inﬂiximab at
week 14 was associated with sustained clinical response. For
certolizumab pegol, an association was observed between serum
drug concentrations at week 8 and endoscopic response and
remission at week 10 in the MUSIC trial.56 In a post hoc analysis
of the ACT 1 and 2 trials, higher concentrations of inﬂiximab
were associated with clinical response, remission, and mucosal
healing in patients with UC at different time points during induc-
tion and maintenance treatment.57 Similar observations were made
in the ULTRA 2 trial, where the proportion of patients with UC in
remission increased for higher adalimumab concentration quar-
tiles,58 and for golimumab, in the PURSUIT trial, already at week
6, a concentration effect was observed in patients with UC.44 In
a retrospective study by Arias et al in 285 patients with UC,
adequate inﬂiximab trough concentrations at week 14 predicted
relapse-free and colectomy-free survival during long-term follow-
up.59 These and other studies indicate that increasing drug
exposure in some patients might lead to better short-term and
long-term outcomes.
For vedolizumab, an apparent association was observed
between serum drug concentrations and clinical response and
Dulai et al Inﬂamm Bowel Dis  Volume 22, Number 4, April 2016
1002 | www.ibdjournal.org
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
remission at week 6 in CD.24 This association was less pro-
nounced during the subsequent maintenance phase. A similar
observation between serum drug concentrations and clinical
response and remission at week 6 was observed in UC.40 Also
here, the association was less pronounced during the subsequent
maintenance phase, based on quartile analysis. Interestingly,
already after 1 infusion, 95% saturation was observed of a4b7,
indicating to some extent that target saturation is achieved even in
patients with lower drug exposure. Hence, drug concentrations for
vedolizumab may be indicative of some other biological effect
beyond blocking the egress of a4b7, expressing lymphocytes from
the peripheral blood into the gut.
Optimal Cut-points
The optimal serum drug concentration for TNF antagonists
depends on the time point of sampling (induction versus
maintenance) and outcome measure (clinical response or remis-
sion, C-reactive protein, mucosal healing, etc.).57 These thresh-
olds can also differ interindividually and intraindividually
depending on the disease state and severity, as some patients
might require higher drug exposure for induction of remission
than to maintain remission. Table 155,57,59–70 summarizes different
retrospective and prospective studies in IBD that found an asso-
ciation between TNF antagonist trough concentrations and clini-
cal outcomes, and delineated a threshold drug concentration.
Typically, a receiver operating characteristic curve analysis was
performed to assess the sensitivity and speciﬁcity of the obtained
threshold in predicting the chosen outcome measure.
Interestingly, the concentration thresholds were higher when asso-
ciated with long-term outcomes (¼ predictive value) compared
with outcomes assessed at time point of sampling (¼ surrogate
marker). Interestingly, the serum concentration–efﬁcacy relation-
ship has been shown to plateau for inﬂiximab.71 The optimal cut-
point for certolizumab pegol and golimumab is yet to be
determined.
Strategies Available to Optimize
Drug Concentrations
To achieve optimal drug concentrations, providers may
implore various strategies, one of which is the upfront use of
concomitant immunosuppressive therapy to prevent immunoge-
nicity. Data from the SONIC and UC SUCCESS trials in CD and
UC, respectively, showed that the use of concomitant azathioprine
led to higher inﬂiximab trough concentrations in patients on
combination therapy compared with patients who were treated
with inﬂiximab monotherapy.10,11 Similar observations were made
in the COMMIT trial for patients with CD treated with concom-
itant methotrexate.72 The mechanism of action is not entirely clear
but is likely an additive effect of (1) a synergism between both
anti-inﬂammatory drugs leading to a decreased clearance and (2)
an anti-immunogenic protective effect leading to lesser patients
developing antidrug antibodies that cause a faster clearance of
drug. Comparative effectiveness studies assessing the impact of
concomitant immunosuppressive therapy for other biologics is
lacking, but a reasonable conclusion to be made is that the con-
comitant use of immunosuppressive therapy for TNF antagonists
TABLE 1. Drug Concentration Thresholds and Associations with Various Outcome Measures6,7,55,57,59–68,90
CD/UC (N) Drug
Time Point of
Sampling Threshold, mg/mL
Sensitivity %,
Speciﬁcity %, AUC Outcome Measure
IBD (128)60 IFX Induction $2.0 na, na, 0.76 Long-term clinical response after restart ($W52)
UC (112)59 IFX W14 $2.5 81%, 75%, 0.77 Relapse-free survival (6 mo)
IBD (58)61 IFX W14 $4.0 53%, 75%, 0.64 Persistent remission (W54)
CD (144)55 IFX W14 $3.5 64%, 78%, 0.75 Sustained clinical response (throughout W54)
CD (85)62 IFX Maintenance ,0.5 86%, 85%, 093 Clinical loss of response
UC (21)62 IFX Maintenance ,0.8 75%, 100%, 0.90 Clinical loss of response
IBD (103)63 IFX Maintenance ,2.0 76%, 82%, 0.68 Absence of clinical remission
CD (327)64 IFX Maintenance ,2.7 63%, 76%, 0.72 CRP .5 mg/L
CD (483)65 IFX Maintenance $2.8 53%, 78%, 0.68 Biochemical remission (CRP #5 mg/L)
UC (374)57 IFX Maintenance $3.7 65%, 71%, 0.71 Clinical response
IBD (46)66 IFX Maintenance $8.3 71%, 73%, 0.75 Mucosal healing
CD (81)67 IFX Maintenance $5.0 na, na, na Continued response after IMM withdrawal (FU)
UC (73)68 ADA W4 $4.6 80%, 56%, na Clinical response (W12)
UC (73)68 ADA W4 $7.0 80%, 69%, na Sustained clinical response (throughout W52)
CD (71)69 ADA Maintenance $5.9 68%, 71%, 0.75 Clinical remission
IBD (40)70 ADA Maintenance ,4.9 66%, 85%, 0.77 Absence of mucosal healing
ADA, adalimumab; AUC, area under curve; CD, Crohn’s disease; CRP, C-reactive protein; FU, follow-up; IBD, inﬂammatory bowel disease; IFX, inﬂiximab; na, not available; UC,
ulcerative colitis; W, week.
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would confer improved efﬁcacy given the clear impact on phar-
macokinetics.12 The impact of concomitant immunosuppressive
therapy with vedolizumab will need to be explored further.
Another strategy to optimize drug concentrations has
recently emerged, which implores treating based on trough
concentrations to maintain adequate exposure and treatment
response. In an RCT of 69 patients with CD with secondary loss
of response to maintenance inﬂiximab, the implementation of
a therapeutic drug monitoring algorithm to guide treatment
decisions was compared with empiric dose escalation in terms
of cost and efﬁcacy at week 12.73 Health care costs related to CD
were 34% lower for those patients treated in accordance with the
algorithm than by inﬂiximab dose intensiﬁcation. In addition,
disease control, as judged by response rates, was similar between
both groups. A long-term follow-up of the study showed that the
economic beneﬁt of the algorithm-based interventions at inﬂixi-
mab failure is maintained throughout 1 year.74 In the randomized
controlled TAXIT trial including 263 patients with IBD with
stable response to maintenance inﬂiximab therapy, dosing based
on trough concentrations was compared with dosing based on
clinical symptoms and C-reactive protein in terms of efﬁcacy,
safety, and cost-effectiveness.75 This was the ﬁrst prospective
study to conﬁrm the causal relationship between exposure and
effect as dose escalation in patients with suboptimal drug concen-
trations (,3 mg/mL) led to a signiﬁcant increase in the proportion
of patients with CD in remission and a signiﬁcant decrease in
inﬂammatory markers. Moreover, the study showed for the ﬁrst
time that the inﬂiximab dose can be safely reduced in patients
who have supratherapeutic inﬂiximab trough concentrations (.7
mg/mL), which led to 28% drug cost savings. One year after dose
optimizing all patients, the proportion of patients who continued
inﬂiximab dosing based on trough concentrations did not differ
from standard care follow-up, but signiﬁcantly more patients from
the latter group needed rescue therapy because of disease ﬂares.
These results indicate a role for therapeutic drug monitoring in
clinical practice not only at the time of loss of response but also
during routine follow-up in patients to maximize cost-
effectiveness of TNF antagonists.
KEY BIOLOGICS AND SMALL MOLECULES
IN DEVELOPMENT
Newer biologics and small molecules in phase 3 and 2
development aim to expand on our current treatment options by
targeting various pathways within T-cell activation, adhesion, and
proinﬂammatory cytokine activation. Of these various studies, 2
novel agents are anticipated to complete phase 3 trials within the
next year, ustekinumab and tofacitinib, and several other agents
have shown promising results in phase 2 trials.
Ustekinumab
IL-12 and IL-23 are proinﬂammatory cytokines that induce
Th1 or Th17 differentiation, and these cytokines have been linked
to the pathogenesis of CD.76 Ustekinumab, a fully humanized
monoclonal antibody, blocks the biological activity of IL-12
and IL-23 through a common p40 subunit and is currently under-
going phase 3 trials for use in moderate to severely active patients
with CD who have failed or are intolerant to TNF antagonists and
in TNF antagonists naive patients. Within the phase 2b trials,
although an appreciable difference was not noted for achieving
induction of clinical remission at week 6 (placebo: 10.6% versus 1
mg/kg: 16%, 3 mg/kg: 15.9%, and 6 mg/kg: 12.2%, P . 0.2 for
all comparisons), there was a trend toward signiﬁcance at week 8
(placebo: 10.6% versus 1 mg/kg: 17.6%, P ¼ 0.11; 3 mg/kg
18.2% P ¼ 0.08; and 6 mg/kg 18.3%, P ¼ 0.07). Furthermore,
among those who had initially responded to induction therapy,
ustekinumab maintenance therapy (90 mg at weeks 8 and 16)
resulted in a higher rate of clinical remission (41.7% versus
27.4%, P ¼ 0.03) and steroid-free remission (30.6% versus
17.8%, P ¼ 0.048) when compared with placebo at week 22.
Mongersen
Another cytokine linked to the pathogenesis of mucosal
inﬂammation in CD is transforming growth factor (TGF)-b1.
TGF-b1 is an immunosuppressive cytokine that functions as
a negative regulator of T-cell immune responses. Within CD, it
has been demonstrated that SMAD7, an inhibitor of TGF-b1 sig-
naling, is overexpressed in patients with CD and inhibition of
SMAD7 restores TGF-b1 signaling, and allows for it to inhibit
cytokine production.77 Accordingly, SMAD7 offers a potential
therapeutic target for managing CD-related mucosal inﬂamma-
tion. Mongersen, an oral SMAD7 antisense oligonucleotide, has
recently completed phase 2 studies and will soon be evaluated in
phase 3 investigation.78 Within the phase 2 trial, the proportion of
patients who achieved clinical remission by day 15 and main-
tained clinical remission for at least 2 weeks was signiﬁcantly
higher in the 160 mg (65%) and 40 mg (55%) groups, as com-
pared with the 10 mg group (12%, P , 0.001) and placebo (10%,
P, 0.001). The proportion of patients in clinical remission at day
84 was similarly signiﬁcantly higher in the 160 mg (67%) and 40
mg (63%) groups as compared with the 10 mg (29%, P , 0.001)
and placebo (21%, P , 0.001).
Tofacitinib
Traditionally, biological agents have targeted speciﬁc
receptors or cytokine activity. Tofacitinib, however, is an oral
small molecule that selectively inhibits the Janus kinase family,
tyrosine kinases that mediate signal transduction for multiple
cytokines. By blocking a common signaling molecule used by
several pivotal proinﬂammatory cytokines, tofacitinib inhibits
both T-cell and B-cell function while preserving regulatory T-cell
function.79 Although it is not clear that the JAK signaling pathway
is dysregulated in the setting of IBD, the efﬁcacy of tofacitinib in
rheumatoid arthritis and psoriasis has led investigators to study its
potential efﬁcacy in IBD. Phase 2 trials were subsequently con-
ducted for CD and UC.79,80 Outcomes with tofacitinib in patients
with CD was less than ideal, and the phase 2 study failed to meet
its primary outcome. In UC, however, rates of clinical remission
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with tofacitinib were dose dependent, and patients who were
treated with 3 mg (33% remission, P ¼ 0.01), 10 mg (48% remis-
sion, P , 0.001), or 15 mg (41% remission, P , 0.001) were
signiﬁcantly more likely to achieve clinical remission at week 8
when compared with placebo (10% remission). In addition, at 8
weeks after therapy, endoscopic remission in UC was achieved in
2% of patients receiving placebo as compared with 18% of pa-
tients, receiving 3 mg of tofacitinib (P ¼ 0.01), 30% of those
receiving 10 mg (P , 0.001), and 27% of those receiving 15
mg (P , 0.001).
Ozanimod
Another opportunity to modulate inﬂammation in IBD is
through inhibition of lymphocyte trafﬁcking. This can be
accomplished by inhibiting ligand interactions at the mucosal
level (anti-integrins) or by inhibiting central trafﬁcking through
lymph nodes. In order for lymphocytes to leave the lymph nodes,
the S1P (sphingosine-1-phosphate) receptors on the surface of
lymphocytes must bind to S1P which expressed as a gradient
along lymphatic endothelium. By modulating S1P, S1P receptors
on the surface of lymphocytes can be internalized and degraded,
thereby preventing lymphocyte migration out of the lymph node.
This “trapping” reduces circulating effector T-cells, which in turn
leads to a selective suppression of the immune system. Ozanimod,
an oral S1P modulator, has recently completed phase 2 trials
and begun phase 3 trials in UC. Within the phase 2 trial
(TOUCHSTONE), the proportion of patients achieving clinical
remission at week 8 was higher in the 1.0 mg group (16.4%, P ¼
0.0482) and 0.5 mg group (13.8%, P ¼ 20.142) when compared
with placebo, and endoscopic improvement was also achieved more
often in the 1.0 mg group (34%, P ¼ 0.002) and 0.5 mg group
(28%, P ¼ 0.0348) when compared with placebo (12%).81
COMPARATIVE EFFECTIVENESS SUMMARY
Taken together, variations in trial populations, outcome
assessment, and heterogeneity across studies make it difﬁcult to
directly compare treatment efﬁcacy of biologics currently
approved for use in moderate to severely active CD or UC. A
reasonable conclusion for CD is that treatment outcomes with
inﬂiximab and adalimumab are more well established, and these
drugs can be more closely monitored using drug concentration
assessments, whereas the efﬁcacy of vedolizumab is time
dependent, and it is yet to be determined what impact vedolizu-
mab may have on long-term risks of complications, hospitaliza-
tion, and surgery. Therefore, in patients who are steroid dependent
or resistant, or in those at high risk for disease-related complica-
tions (Table 2),39,82–101 inﬂiximab or adalimumab may be the more
appropriate therapy. In patients with CD where time to remission
is not as signiﬁcant of a concern and patients are not felt to be
a high risk for disease-related complications, the potential-
enhanced safety proﬁle of vedolizumab may be particularly
appealing and beneﬁcial in certain populations (i.e., elderly or
previous infectious complications). In these settings, vedolizumab
for induction and maintenance of remission may be a more appro-
priate treatment option. For ﬁstulizing or penetrating disease
activity in CD, these data are more straightforward, and although
other agents have reported ﬁstula healing as a secondary endpoint,
only inﬂiximab has been studied with ﬁstula healing as the pri-
mary endpoint within RCTs. Therefore, inﬂiximab should remain
the ﬁrst-line agent for all patients with CD with ﬁstulizing and/or
penetrating disease activity, and adalimumab should be consid-
ered a second-line agent if inﬂiximab fails despite appropriate
drug concentrations.22,23,30,31,102,103
In UC, data would suggest that either inﬂiximab or
vedolizumab would be appropriate as the ﬁrst-line therapy given
the similar within-study treatment effect size for induction and
maintenance of remission, and mucosal healing. Similar to CD,
long-term data for prevention of hospitalization and surgery with
vedolizumab are lacking. Therefore, inﬂiximab is likely the more
appropriate treatment option for patients at high risk for disease-
related complications (Table 2), particularly considering a clear
approach exists for optimizing inﬂiximab concentrations and
treatment outcomes. Vedolizumab may be an appropriate alterna-
tive in certain populations, where the enhanced safety proﬁle may
be beneﬁcial.104 The exact positioning of adalimumab within cur-
rent treatment algorithms remains unclear. It has been suggested
that the reduced efﬁcacy as compared with inﬂiximab is a result of
underdosing, and clinical trials are currently underway to address
this question through a high-dose induction regimen.
For key biologics in development, although long-term data
are needed to understand the exact positioning of these biologics,
they have demonstrated signiﬁcant promise for use as the ﬁrst-line
or second-line therapy. Ustekinumab will likely be a key
TABLE 2. Predictors of a More Aggressive Disease
Course and Treatment Outcomes in IBD10,82–99
Crohn’s disease
Perianal, stricturing, or penetrating disease
Small bowel involvement
Younger age at diagnosis and disease duration (.2 yr)
Requirement for steroids at initial diagnosis
Inﬂammatory burden (extensive and deep ulcerations, high CRP
without normalization)
Biological drug concentrations and concomitant immunosuppressive
use
Ulcerative colitis
Younger age at diagnosis or gender
Extraintestinal manifestations
High inﬂammatory burden (CRP, ESR, albumin, extensive colitis, or
deep ulcerations on endoscopy)
Hospitalization for a disease ﬂare or need for steroids
Biological drug concentrations and concomitant immunosuppressive
use
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
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biological agent for use in patients with CD who have failed or are
intolerant to TNF antagonists, particularly when considering that
the existing options for the patients refractory to or intolerant of
TNF antagonists are limited, and drug concentration monitoring to
optimize treatment efﬁcacy is currently being explored for
ustekinumab in other arenas.105 Mongersen seems very promising
given it achieved the highest treatment effect size ever seen induc-
tion therapy in CD, but there were no data on mucosal healing, and
providers should note that the population of patients enrolled was
highly selective, and the drug is designed to only release in the
terminal ileum and right colon, limiting its application to a subpop-
ulation of patients with CD. For UC, tofacitinib and ozanimod are
oral small molecule inhibitors with signiﬁcant promise, and they
offer the advantage of not being restricted by traditional factors
known to impact drug clearance for currently available biologics.
Therefore, in patients at high risk for drug clearance, they may
provide alternative strategies to optimize treatment efﬁcacy.
FUTURE CONSIDERATIONS: HEALTH CARE
REFORM AND TREATING TO A TARGET OF
BIOLOGICAL VALUE
Health care has begun to shift away from the current fee for
service model, toward a value-based payment model, where
providers and health care systems are reimbursed according to
treatment outcomes and disease-speciﬁc benchmarks (pay for
performance).106–108 With most of costs being driven by biologics
in IBD, it can be expected that in the near future, reimbursement
for IBD care will be directly linked to how we use our biological
agents and how effectively we achieve key long-term outcomes
such as clinical remission, mucosal healing, and hospitalization or
surgery. Traditionally, our treatment strategies have largely been
based on the premise that the value of therapy with biological
agents in IBD is for the most part, a function of treatment effect
size. The larger the effect size, the greater the value. It is impor-
tant, however, to consider that treatment effect size is dependent
on the population in which the drug is used, and treatment value is
also a function of treatment cost and adherence, with adherence
being driven by treatment safety and patient preference.109–112
Therefore, to truly optimize the value of current biological agents
and the positioning of future therapies, providers will need to
individualize treatment decisions, and IBD will need to shift
toward personalized medicine.
Predicting Disease Course: Prescribing the
Right Biological Therapy to the Right Patients
at the Right Time
Several predictors have been identiﬁed for disease pro-
gression and/or response to biological therapy (Table 2).39,82–101
Individually, these factors may help providers when considering
how to use and monitor biologics in clinical practice, but they are
unable to accurately and consistently predict individual outcomes
and/or disease progression. Recent efforts have now transitioned
toward the creation of integrated composite bioproﬁles that
incorporate a patient’s genotype, phenotype, clinical course, and
pharmacokinetics to predict their individualized natural course of
disease progression and the potential anticipated beneﬁt with bio-
logical therapies. Siegel et al113,114 have created a web-based tool
for use in adults and children that predicts disease course through
the integration of patient characteristics, serologic markers, NOD2
status, and medication exposure. Although the model demon-
strated good concordance (adults: concordance index 0.73, pedi-
atrics: concordance index 0.81) when validated against internal
and external cohorts, models that built on well-phenotyped pro-
spective cohorts enrolled at the time of diagnosis are still needed.
The mechanism of action of TNF antagonists in IBD is
a combined additive effect of both systemic and local functions,
and therefore, local monitoring of TNF in tissues may provide
predictive capability for treatment outcomes.115 In a cross-
sectional study in 30 patients with IBD treated with either inﬂix-
imab or adalimumab, TNF and TNF antagonists concentrations in
serum were compared with concentrations in tissue biopsies and
correlated with endoscopic and histological disease activity.116 A
positive correlation was found between TNF antagonists in serum
and tissue for uninﬂamed, but not for inﬂamed tissue. This
approach could similarly be applied to other biologics, where serum
or tissue levels of receptors and ligands (i.e., MadCAM-1)117 could
be measure to determine treatment efﬁcacy and optimization.
Optimizing Adherence: Comparative
Effectiveness of Treatment Durability
The efﬁcacy of biological agents is signiﬁcantly impacted
by the ability of patients to remain on therapy for long term.
Providers must therefore balance the available data on treatment
efﬁcacy against treatment safety and “durability.” A recent meta-
analysis attempted to quantify this by assessing treatment dura-
bility or the likelihood that a patient will stay on therapy.118 By
comparing the number of patients who discontinued therapy
against the expected efﬁcacy, the authors created a new metric
of treatment durability (number needed to discontinue/number
needed to treat). They were able to demonstrate that biological
therapies have a higher durability when compared with immuno-
suppressive agents (azathioprine, 6-mercaptopurin, and metho-
trexate) in CD, and among biologics’ antitrafﬁcking agents
carried the greatest likelihood for durability given their enhanced
safety proﬁle. Although this novel approach to categorizing treat-
ment durability is promising, these data are obtained solely from
RCTs imploring strict inclusion criteria, and future comparisons
will need to assess treatment durability in the community setting
while accounting for other factors known to impact adherence
(access to care and mental health).
Reductions in Costs: Positioning of Biosimilars
Biosimilar TNF antagonist monoclonal antibodies are
currently under development, and a recent biosimilar of inﬂiximab
(CT-P13) has been approved for use in several international
communities. The main advantage of these agents is the reduction
in cost associated with their use, and if bioequivalence and
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interchangeability can be demonstrated in patients with IBD, it is
estimated that biosimilars may result in a 40% reduction in
treatment-related costs.119 Given current guidelines only require
in vitro data on similarity to the reference product and far fewer
clinical studies are needed for biosimilars, the approval of these
agents may create an opportunity for providers to further optimize
treatment efﬁcacy through approaches that have traditionally been
limited by treatment costs (i.e., early use of biological agents in
patients with mild to moderate disease activity and/or the combi-
nation of highly selective biological agents with distinct mecha-
nisms of action, anti-integrins, and TNF antagonists, for the
induction and/or maintenance of clinical remission and mucosal
healing). However, interchangeability will need to be demon-
strated in robust clinical trials for these agents to reach their full
potential for cost reduction.
SUMMARY
In conclusion, evolving treatment strategies and biological
therapies offers an opportunity to optimize disease outcomes in
moderate to severely active IBD, but providers will need to
consider their relative comparative effectiveness and pharmaco-
kinetics when using them in practice. Therapies with an
established impact on short-term (response, remission, and steroid
withdrawal) and long-term (hospitalization and surgery) out-
comes, with drug monitoring capability where drug concentra-
tions are clearly linked to improved outcomes, will be the
favorable ﬁrst-line agents. In certain populations, the enhanced
safety or pharmacokinetic proﬁles of newer biologics and small
molecule inhibitors may be advantageous. Ultimately, treatment
algorithms will need to shift toward a personalized approach,
where individual preferences, safety proﬁles, phenotypes, and
treatment predictors are integrated into therapeutic decisions and
monitoring in an effort to optimize the value of these agents.
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